American College of Cardiology 2022: New Data on Lipids From the APOLLO Study

Anum Saeed, MD


April 06, 2022

In looking ahead to the upcoming American College of Cardiology Conference in Washington DC, Anum Saeed, MD, speculates on forthcoming data from current studies and concentrates on one in particular, APOLLO, a phase 1 study that examines the efficacy of SLN360, an siRNA agent that lowers lipoprotein (a) levels.

In the absence of any approved medications for treating lipoprotein (a), the impending presentation of these data by Dr Steven Nissen fuels excitement surrounding the anticipated positive results, which not only could translate into long-awaited benefits for patients affected by this lipid disorder, but also could provide a forward glance to other potential applications of this therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.